The FDA has granted priority review to nab-paclitaxel in combination with gemcitabine for the first-line treatment of patients with metastatic pancreatic cancer.

A late-stage trial investigating inotuzumab ozogamicin as a treatment for patients with aggressive non-Hodgkin lymphoma has been halted after interim data showed the agent was unlikely to improve survival.

This article summarizes 4 abstracts that will be discussed at the 49th Annual ASCO Meeting, focused on the treatment of patients with head and neck cancer.

A new measure of tumor heterogeneity in patients with head and neck squamous cell carcinoma (HNSCC) was significantly associated with tumor progression and adverse treatment outcomes.

A high-profile case of a medical decision being based primarily on the results of a genetic test has prompted a national discussion on the benefits and risks associated with acting on the results of such a test.

The FDA approved radium RA 223 dichloride for the treatment of symptomatic metastatic castration-resistant prostate cancer that has spread to the bones but not to any other organs.

The FDA concurrently approved erlotinib along with a companion diagnostic to be used together in the first-line treatment of patients with metastatic non-small cell lung cancer harboring a specific EGFR mutation.

The treatment of bone metastases in prostate cancer has changed over the years, and several options are now either available or under development.